Skip to content

A clinical study to check the effectiveness and safety of the medicine Zolpidem Tartrate in the patients of Insomnia with hypertension.

An open label single arm non-comparative study to assess effectiveness and safety of Zolpidem Tartrate in patients of insomnia with hypertension

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/12/016688
Enrollment
50
Registered
2018-12-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension Health Condition 2: G470- Insomnia

Interventions

Intervention1: Zolpidem Tartrate: Zolpidem is indicated for the short-term treatment of insomnia. The treatment should be taken in a single intake and not be re-administered during the same night. The

Sponsors

Dr Rajiv D Karnik
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Healthy adult patients (both male and female) who are 18 to 2. Must experience sleep disturbances (difficulty in sleep initiation or middle of the night awakening or early morning awakening or poor quality of sleep) at least 3 nights/week, based on historical data. 3. Insomnia Severity Index score of >=8 at screening 4. Patients with a clinical diagnosis of Hypertension (at least one year prior to screening). 5. Patient willing to sign informed consent form.

Exclusion criteria

Exclusion criteria: 1. Currently using prescription and non-prescription sedative drugs given for more than 2 days for the purpose of sleep disturbances or to relieve jet lag with the last 28 days proceeding to enrollment. 2. Shift work or requirement for a regular change in sleep schedule by at least six hours with in the previous 28 days. 3. Evidence of any medical condition as revealed by history, physical examination or laboratory assessment which may interfere with administration or assessment of study medication 4. Current alcohol or drug abuse 5. Patients viewed by the investigator as not being able to complete the study. 6. History of obstructive sleep apnoea or restless leg syndrome. 7. History of myasthenia gravis. 8. History of hepatic insufficiency. 9. History of respiratory depression. 10. Patients with a known history of hypersensitivity to Zolpidem tartrate or any of the inactive ingredients.

Design outcomes

Primary

MeasureTime frame
To measure the change in Insomnia severity index (ISI) ScoreTimepoint: Baseline visit to Day 21 visit

Secondary

MeasureTime frame
To measure the change in HRQoL ScoreTimepoint: Baseline visit to Day 21 visit

Countries

India

Contacts

Public ContactDr Rajiv D Karnik

Dr.Karniks Cardiac Clinic

docrajiv@hotmail.com9820125257

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026